Literature DB >> 15987062

Magnetic resonance imaging of the liver: review of techniques and approach to common diseases.

Diego R Martin1, Richard C Semelka.   

Abstract

MR imaging examination of the liver should use a combination of single-shot T2W and breath-hold T1W images, and include gadolinium enhancement with acquisition of multiple phases. MR provides superior characterization of liver masses than CT, and multi-phase gadolinium enhancement including a properly timed arterial phase is critical. The T1 weighted pre-contrast images must include in-phase/out-of-phase acquisitions, to assess hepatic lipid and or iron content, and dynamically enhanced post-gadolinium images. Timing of the arterial phase images is also critical for demonstration of acute hepatitis. The timing of the venous and equilibrium phase images are less critical, and are important for grading more severe acute hepatitis, demonstration of fibrosis, and for delineating vascular abnormalities. In cirrhosis, dynamic post-gadolinium images are critical for detection and characterization of regenerative or dysplastic nodules, and HCC. The same sequences useful for liver evaluation provide a comprehensive evaluation of all the soft tissues of the abdomen, and allow depiction of most of the important diseases, thus facilitating use of a universal protocol for abdominal imaging.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15987062     DOI: 10.1053/j.sult.2005.02.009

Source DB:  PubMed          Journal:  Semin Ultrasound CT MR        ISSN: 0887-2171            Impact factor:   1.875


  2 in total

1.  Magnetic resonance imaging: Review of imaging techniques and overview of liver imaging.

Authors:  Santhi Maniam; Janio Szklaruk
Journal:  World J Radiol       Date:  2010-08-28

2.  Iron overload: accuracy of in-phase and out-of-phase MRI as a quick method to evaluate liver iron load in haematological malignancies and chronic liver disease.

Authors:  J M Virtanen; T K Pudas; J A Ratilainen; J P Saunavaara; M E Komu; R K Parkkola
Journal:  Br J Radiol       Date:  2011-03-08       Impact factor: 3.039

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.